Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.05 USD
-0.04 (-3.67%)
Updated May 24, 2024 03:59 PM ET
After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Earnings News For KPTI
-
Karyopharm Therapeutics: Q1 Earnings Snapshot
-
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics: Q4 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
-
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
-
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
-
Karyopharm Therapeutics: Q3 Earnings Snapshot
-
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q2 Earnings Snapshot
-
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q1 Earnings Snapshot
-
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
-
Karyopharm Therapeutics: Q4 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
-
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
-
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
-
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q3 Earnings Snapshot
-
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q2 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates